Polyphosphazene polyelectrolytes are synthetic, biodegradable polymers that have shown great potential in vaccine and drug delivery applications. Numerous investigations in laboratory animals have revealed that polyphosphazenes are also potent immunological adjuvants that can dramatically enhance the magnitude, quality and duration of immune responses to a variety of bacterial and viral vaccine antigens. Evidence is accumulating that these polymers have potent adjuvant activity in large animals as well. Interestingly, polyphosphazenes can be combined with novel immune modulatory agents resulting in even more potent immune activity and protection against experimental infection. While most reports are on the activity of polyphosphazenes in aqueous formulations, these polymers can also be easily made into microparticles, making them especially attractive for mucosal delivery. The mechanisms which mediate the adjuvant activity of polyphosphazenes are not fully understood, but there is evidence to suggest that activation of innate immunity may be involved. Further research and development of polyphosphazene adjuvants is warranted to fully explore their potential in the delivery of vaccines and immunotherapeutic agents.
A reliable laboratory animal model would be useful for the study of immune responses to trichomoniasis, a sexually transmitted disease of human beings and cattl...
19 February 2022 in International Journal of One Health
Antimicrobial resistance (AMR) is currently recognized as a major emerging threat to human and animal health. The burden of antimicrobial-resistant infections affects the economy in developed and developing countries. There is a rapid rise in AMR in human and veterinary medicine globally. AMR profiles are poorly documented in Fiji, and limited data are accessible. Fiji currently has no national veterinary antibiotic resistance surveillance network or regulations and guidelines on veterinary drug use. However, available literature shows that although human drugs are better managed than veterinary drugs, the knowledge is still constrained and dispersed. Furthermore, Fiji was chosen as a case study to develop a prototype AMR surveillance and control in the Pacific region. Pacific Island countries share similar geographic and climatic conditions. Currently, the Australian Centre for International Agricultural Research has funded an AMR project that addresses some gaps in managing AMR in the region. The project is the first to adopt the One Health approach to research the AMR in humans, animals, and the Pacific region's environment. Combating AMR needs human health and veterinary personnel to work with all other stakeholders. Continuous surveillance for resistant clinical isolates in humans and animals and the development of appropriate policy intervention measures in human and veterinary drug use are necessary to alleviate AMR burden. Therefore, there is a need to educate farmers, human patients, and the public on the fight against AMR. In addition, AMR data are necessary to develop effective AMR control strategies. This review gives a comprehensive information assessment on AMR in Fiji and the other South Pacific Islands in relation to global trends. Suggestions on the most appropriate ways of effectively managing AMR in Fiji have been made.